CoChat
Sign Up
Cited by 325

The DOI matches its Crossref record.

MYH9: Structure, functions and role of non-muscle myosin IIA in human disease

Pecci, Alessandro, Ma, Xuefei, Savoia, Anna, Adelstein, Robert S.·2018·Gene
DOI 10.1016/j.gene.2018.04.048PMC PMC5970098
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.gene.2018.04.048

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 142

  1. Adelstein, 1975, Phosphorylation of platelet myosin increases actin-activated myosin ATPase activity, Nature, 256, 597, 10.1038/256597a0 · DOI
  2. Baird, 2017, Local pulsatile contractions are an intrinsic property of the myosin 2A motor in the cortical cytoskeleton of adherent cells, Mol. Biol. Cell, 28, 240, 10.1091/mbc.e16-05-0335 · DOI
  3. Badirou, 2015, Distinct localizations and roles of non-muscle myosin II during proplatelet formation and platelet release, J. Thromb. Haemost., 13, 851, 10.1111/jth.12887 · DOI
  4. Beach, 2015, Myosin II isoform co-assembly and differential regulation in mammalian systems, Exp. Cell Res., 334, 2, 10.1016/j.yexcr.2015.01.012 · DOI
  5. Beach, 2011, Myosin II isoform switching mediates invasiveness after TGF-beta-induced epithelial-mesenchymal transition, Proc. Natl. Acad. Sci. U. S. A., 108, 17991, 10.1073/pnas.1106499108 · DOI
  6. Beach, 2011, Analysis of the role of Ser1/Ser2/Thr9 phosphorylation on myosin II assembly and function in live cells, BMC Cell Biol., 12, 52, 10.1186/1471-2121-12-52 · DOI
  7. Beach, 2014, Nonmuscle myosin II isoforms coassemble in living cells, Curr. Biol., 24, 1160, 10.1016/j.cub.2014.03.071 · DOI
  8. Beckerman, 2017, Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice, Nat. Med., 23, 429, 10.1038/nm.4287 · DOI · Paper page
  9. Balduini, 2008, Adhesive receptors, extracellular proteins and myosin IIA orchestrate proplatelet formation by human megakaryocytes, J. Thromb. Haemost., 6, 1900, 10.1111/j.1538-7836.2008.03132.x · DOI
  10. Balduini, 2013, Diagnosis and management of inherited thrombocytopenias, Semin. Thromb. Hemost., 39, 161, 10.1055/s-0032-1333540 · DOI
  11. Billington, 2015, Myosin 18A coassembles with nonmuscle myosin 2 to form mixed bipolar filaments, Curr. Biol., 25, 942, 10.1016/j.cub.2015.02.012 · DOI
  12. Bresnick, 2015, S100 proteins in cancer, Nat. Rev. Cancer, 15, 96, 10.1038/nrc3893 · DOI
  13. Burgess, 2007, Structures of smooth muscle myosin and heavy meromyosin in the folded, shutdown state, J. Mol. Biol., 372, 1165, 10.1016/j.jmb.2007.07.014 · DOI
  14. Cechova, 2018, MYH9 E1841K mutation augments proteinuria and podocyte injury and migration, J. Am. Soc. Nephrol., 29, 155, 10.1681/ASN.2015060707 · DOI
  15. Chen, 2007, The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway, Blood, 110, 171, 10.1182/blood-2007-02-071589 · DOI
  16. Cheng, 2011, Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with the progression of IgA nephropathy in Chinese, Nephrol. Dial. Transplant., 26, 2544, 10.1093/ndt/gfq768 · DOI
  17. Conti, 2004, Defects in cell adhesion and the visceral endoderm following ablation of nonmuscle myosin heavy chain II-A in mice, J. Biol. Chem., 279, 41263, 10.1074/jbc.C400352200 · DOI
  18. Conti, 2015, Conditional deletion of nonmuscle myosin II-A in mouse tongue epithelium results in squamous cell carcinoma, Sci. Rep., 5, 14068, 10.1038/srep14068 · DOI
  19. Cooke, 2012, Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans, Nephrol. Dial. Transplant., 27, 1505, 10.1093/ndt/gfr522 · DOI
  20. Craig, 1983, Light-chain phosphorylation controls the conformation of vertebrate non-muscle and smooth muscle myosin molecules, Nature, 302, 436, 10.1038/302436a0 · DOI
  21. Crish, 2013, Keratin 5-Cre-driven excision of nonmuscle myosin IIA in early embryo trophectoderm leads to placenta defects and embryonic lethality, Dev. Biol., 382, 136, 10.1016/j.ydbio.2013.07.017 · DOI
  22. Clark, 2008, The alpha-kinases TRPM6 and TRPM7, but not eEF-2 kinase, phosphorylate the assembly domain of myosin IIA, IIB and IIC, FEBS Lett., 582, 2993, 10.1016/j.febslet.2008.07.043 · DOI
  23. Clark, 2008, TRPM7 regulates myosin IIA filament stability and protein localization by heavy chain phosphorylation, J. Mol. Biol., 378, 790, 10.1016/j.jmb.2008.02.057 · DOI
  24. Cross, 2006, Branching morphogenesis during development of placental villi, Differentiation, 74, 393, 10.1111/j.1432-0436.2006.00103.x · DOI
  25. Dahan, 2014, The tumor suppressor Lgl1 forms discrete complexes with NMII-A and Par6alpha-aPKCzeta that are affected by Lgl1 phosphorylation, J. Cell Sci., 127, 295
  26. D'Apolito, 2002, Cloning of the murine nonmuscle heavy chain myosin IIA gene, ortholog of human MYH9 responsible for May-Hegglin, Sebastian, Fechtner, and Epstein syndromes, Gene, 286, 215, 10.1016/S0378-1119(02)00455-9 · DOI
  27. De Rocco, 2009, Identification of the first duplication in MYH9-related disease: a hot spot for unequal crossing-over within exon 24 of the MYH9 gene, Eur. J. Med. Genet., 52, 191, 10.1016/j.ejmg.2009.01.006 · DOI
  28. Derycke, 2011, The role of non-muscle myosin IIA in aggregation and invasion of human MCF-7 breast cancer cells, Int. J. Dev. Biol., 55, 835, 10.1387/ijdb.113336ld · DOI
  29. Dong, 2005, Genotype-phenotype correlation in MYH9-relatedthrombocytopenia, Br. J. Haematol., 130, 620, 10.1111/j.1365-2141.2005.05658.x · DOI
  30. Dulyaninova, 2013, The heavy chain has its day: regulation of myosin-II assembly, BioArchitecture, 3, 77, 10.4161/bioa.26133 · DOI
  31. Dulyaninova, 2007, Myosin-IIA heavy-chain phosphorylation regulates the motility of MDA-MB-231 carcinoma cells, Mol. Biol. Cell, 18, 3144, 10.1091/mbc.e06-11-1056 · DOI
  32. Ebrahim, 2013, NMII forms a contractile transcellular sarcomeric network to regulate apical cell junctions and tissue geometry, Curr. Biol., 23, 731, 10.1016/j.cub.2013.03.039 · DOI
  33. Eddinger, 2007, Myosin II isoforms in smooth muscle: heterogeneity and function, Am. J. Phys. Cell Physiol., 293, C493, 10.1152/ajpcell.00131.2007 · DOI
  34. Favier, 2013, First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia, Pediatrics, 132, e793, 10.1542/peds.2012-3807 · DOI
  35. Favier, 2018, Eltrombopag to treat thrombocytopenia during last month of pregnancy in a woman with MYH9-related disease: a case report, A A Pract., 10, 10, 10.1213/XAA.0000000000000621 · DOI
  36. Foth, 2006, New insights into myosin evolution and classification, Proc. Natl. Acad. Sci. U. S. A., 103, 3681, 10.1073/pnas.0506307103 · DOI
  37. Genovese, 2010, Association of trypanolytic ApoL1 variants with kidney disease in African Americans, Science, 329, 841, 10.1126/science.1193032 · DOI · Paper page
  38. Golomb, 2004, Identification and characterization of nonmuscle myosin II-C, a new member of the myosin II family, J. Biol. Chem., 279, 2800, 10.1074/jbc.M309981200 · DOI
  39. Greinacher, 2017, Diagnosis of inherited platelet disorders on a blood smear: a tool to facilitate worldwide diagnosis of platelet disorders, J. Thromb. Haemost., 15, 1511, 10.1111/jth.13729 · DOI
  40. Gresele, 2013, Apparent genotype-phenotype mismatch in a patient with MYH9-related disease: when the exception proves the rule, Thromb. Haemost., 110, 618, 10.1160/TH13-02-0175 · DOI
  41. Grum-Schwensen, 2005, Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene, Cancer Res., 65, 3772, 10.1158/0008-5472.CAN-04-4510 · DOI
  42. Han, 2011, Renal manifestations of patients with MYH9-related disorders, Pediatr. Nephrol., 26, 549, 10.1007/s00467-010-1735-3 · DOI
  43. Heissler, 2013, Nonmuscle myosin-2: mix and match, Cell. Mol. Life Sci., 70, 1, 10.1007/s00018-012-1002-9 · DOI
  44. Heissler, 2016, Kinetic adaptations of myosins for their diverse cellular functions, Traffic, 17, 839, 10.1111/tra.12388 · DOI
  45. Heynen, 1988, Congenital macrothrombocytopenia, leukocyte inclusions, deafness and proteinuria: functional and electron microscopic observations on platelets and megakaryocytes, Br. J. Haematol., 70, 441, 10.1111/j.1365-2141.1988.00441.x · DOI
  46. Hosono, 2012, MYBPH inhibits NM IIA assembly via direct interaction with NMHC IIA and reduces cell motility, Biochem. Biophys. Res. Commun., 428, 173, 10.1016/j.bbrc.2012.10.036 · DOI
  47. Hu, 2002, Mutations in human nonmuscle myosin IIA found in patients with May-Hegglin anomaly and Fechtner syndrome result in impaired enzymatic function, J. Biol. Chem., 277, 46512, 10.1074/jbc.M208506200 · DOI
  48. Hundt, 2016, Load-dependent modulation of non-muscle myosin-2A function by tropomyosin 4.2, Sci. Rep., 6, 10.1038/srep20554 · DOI
  49. Ikebe, 1990, Phosphorylation of bovine platelet myosin by protein kinase C, Biochemistry, 29, 2713, 10.1021/bi00463a014 · DOI
  50. Italiano, 1999, Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes, J. Cell Biol., 147, 1299, 10.1083/jcb.147.6.1299 · DOI
  51. Jung, 2008, Head-head and head-tail interaction: a general mechanism for switching off myosin II activity in cells, Mol. Biol. Cell, 19, 3234, 10.1091/mbc.e08-02-0206 · DOI
  52. Kahr, 2009, Megakaryocyte and platelet abnormalities in a patient with a W33C mutation in the conserved SH3-like domain of myosin heavy chain IIA, Thromb. Haemost., 102, 1241, 10.1160/TH09-02-0119 · DOI
  53. Kao, 2008, MYH9 is associated with nondiabetic end-stage renal disease in African Americans, Nat. Genet., 40, 1185, 10.1038/ng.232 · DOI
  54. Kas, 2017, Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma, Nat. Genet., 49, 1219, 10.1038/ng.3905 · DOI
  55. Kassianidou, 2017, Activation of ROCK and MLCK tunes regional stress fiber formation and mechanics via preferential myosin light chain phosphorylation, Mol. Biol. Cell, 28, 3832, 10.1091/mbc.e17-06-0401 · DOI
  56. Katono, 2015, Prognostic significance of MYH9 expression in resected non-small cell lung cancer, PLoS One, 10, 10.1371/journal.pone.0121460 · DOI
  57. Kaushansky, 2015, Thrombopoiesis, Semin. Hematol., 52, 4, 10.1053/j.seminhematol.2014.10.003 · DOI
  58. Kawamoto, 1991, Chicken nonmuscle myosin heavy chains: differential expression of two mRNAs and evidence for two different polypeptides, J. Cell Biol., 112, 915, 10.1083/jcb.112.5.915 · DOI
  59. Kawamoto, 1989, In situ phosphorylation of human platelet myosin heavy and light chains by protein kinase C, J. Biol. Chem., 264, 2258, 10.1016/S0021-9258(18)94170-0 · DOI
  60. Kim, 2005, Disease-associated mutations and alternative splicing alter the enzymatic and motile activity of nonmuscle myosins II-B and II-C, J. Biol. Chem., 280, 22769, 10.1074/jbc.M503488200 · DOI
  61. Kim, 2016, Genetic association of MYH genes with hereditary hearing loss in Korea, Gene, 591, 177, 10.1016/j.gene.2016.07.011 · DOI
  62. Kiss, 2012, Crystal structure of the S100A4-nonmuscle myosin IIA tail fragment complex reveals an asymmetric target binding mechanism, Proc. Natl. Acad. Sci. U. S. A., 109, 6048, 10.1073/pnas.1114732109 · DOI
  63. Kitamura, 2013, Normal neutrophil myosin IIA localization in an immunofluorescence analysis can rule out MYH9 disorders, J. Thromb. Haemost., 11, 2071, 10.1111/jth.12406 · DOI
  64. Komatsu, 2007, The phosphorylation of myosin II at the Ser1 and Ser2 is critical for normal platelet-derived growth factor induced reorganization of myosin filaments, Mol. Biol. Cell, 18, 5081, 10.1091/mbc.e06-12-1076 · DOI
  65. Kopp, 2010, Glomerular pathology in autosomal dominant MYH9 spectrum disorders: what are the clues telling us about disease mechanism?, Kidney Int., 78, 130, 10.1038/ki.2010.82 · DOI
  66. Kopp, 2008, MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis, Nat. Genet., 40, 1175, 10.1038/ng.226 · DOI
  67. Kopp, 2011, APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy, J. Am. Soc. Nephrol., 22, 2129, 10.1681/ASN.2011040388 · DOI
  68. Kunishima, 2001, Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome), Blood, 97, 1147, 10.1182/blood.V97.4.1147 · DOI
  69. Kunishima, 2003, Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders: association of subcellular localization with MYH9 mutations, Lab. Investig., 83, 115, 10.1097/01.LAB.0000050960.48774.17 · DOI
  70. Kunishima, 2005, First description of somatic mosaicism in MYH9 disorders, Br. J. Haematol., 128, 360, 10.1111/j.1365-2141.2004.05323.x · DOI
  71. Kunishima, 2007, Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations, Eur. J. Haematol., 78, 220, 10.1111/j.1600-0609.2006.00806.x · DOI
  72. Kunishima, 2009, Germinal mosaicism in MYH9 disorders: a family with two affected siblings of normal parents, Br. J. Haematol., 145, 260, 10.1111/j.1365-2141.2009.07584.x · DOI
  73. Kunishima, 2014, Somatic mosaicism in MYH9 disorders: the need to carefully evaluate apparently healthy parents, Br. J. Haematol., 165, 885, 10.1111/bjh.12797 · DOI
  74. Kelley, 2000, Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly, Nat. Genet., 26, 106, 10.1038/79069 · DOI
  75. Lalwani, 2008, Localization in stereocilia, plasma membrane, and mitochondria suggests diverse roles for NMHC-IIa within cochlear hair cells, Brain. Res., 1197, 13, 10.1016/j.brainres.2007.12.058 · DOI
  76. Lalwani, 2000, Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9, Am. J. Hum. Genet., 67, 1121, 10.1016/S0002-9297(07)62942-5 · DOI
  77. Larson, 2006, A product of their environment: do megakaryocytes rely on extracellular cues for proplatelet formation?, Platelets, 17, 435, 10.1080/09537100600772637 · DOI
  78. Lin, 2017, LIMCH1 regulates nonmuscle myosin-II activity and suppresses cell migration, Mol. Biol. Cell, 28, 1054, 10.1091/mbc.e15-04-0218 · DOI
  79. Li, 2006, The S100A4 metastasis factor regulates cellular motility via a direct interaction with myosin-IIA, Cancer Res., 66, 5173, 10.1158/0008-5472.CAN-05-3087 · DOI
  80. Li, 2010, S100A4 regulates macrophage chemotaxis, Mol. Biol. Cell, 21, 2598, 10.1091/mbc.e09-07-0609 · DOI
  81. Liao, 2017, LIM kinase 1 interacts with myosin-9 and alpha-actinin-4 and promotes colorectal cancer progression, Br. J. Cancer, 117, 563, 10.1038/bjc.2017.193 · DOI
  82. Ludowyke, 2006, Phosphorylation of nonmuscle myosin heavy chain IIA on Ser1917 is mediated by protein kinase C beta II and coincides with the onset of stimulated degranulation of RBL-2H3 mast cells, J. Immunol., 177, 1492, 10.4049/jimmunol.177.3.1492 · DOI
  83. Ma, 2012, In vivo studies on nonmuscle myosin II expression and function in heart development, Front. Biosci. (Landmark Ed.), 17, 545, 10.2741/3942 · DOI
  84. Ma, 2014, The role of vertebrate nonmuscle Myosin II in development and human disease, BioArchitecture, 4, 88, 10.4161/bioa.29766 · DOI
  85. Ma, 2010, Ablation of nonmuscle myosin II-B and II-C reveals a role for nonmuscle myosin II in cardiac myocyte karyokinesis, Mol. Biol. Cell, 21, 3952, 10.1091/mbc.e10-04-0293 · DOI
  86. Marigo, 2004, Correlation between the clinical phenotype of MYH9-related disease and tissue distribution of class II non-muscle myosin heavy chains, Genomics, 83, 1125, 10.1016/j.ygeno.2003.12.012 · DOI · Paper page
  87. Mhatre, 2006, Expression of Myh9 in the mammalian cochlea: localization within the stereocilia, J. Neurosci. Res., 84, 809, 10.1002/jnr.20993 · DOI
  88. Milton, 2011, Direct evidence for functional smooth muscle myosin II in the 10S self-inhibited monomeric conformation in airway smooth muscle cells, Proc. Natl. Acad. Sci. U. S. A., 108, 1421, 10.1073/pnas.1011784108 · DOI
  89. Miyagawa, 2013, Targeted exon sequencing successfully discovers rare causative genes and clarifies the molecular epidemiology of Japanese deafness patients, PLoS One, 8, 10.1371/journal.pone.0071381 · DOI
  90. Miyazaki, 2009, Identification of three in-frame deletion mutations in MYH9 disorders suggesting an important hot spot for small rearrangements in MYH9 exon 24, Eur. J. Haematol., 83, 230, 10.1111/j.1600-0609.2009.01274.x · DOI
  91. Moussavi, 1993, Phosphorylation of vertebrate nonmuscle and smooth muscle myosin heavy chains and light chains, Mol. Cell. Biochem., 127-128, 219, 10.1007/BF01076773 · DOI
  92. Neveling, 2013, A post-hoc comparison of the utility of sanger sequencing and exome sequencing for the diagnosis of heterogeneous diseases, Hum. Mutat., 34, 1721, 10.1002/humu.22450 · DOI
  93. Nishikawa, 1984, Protein kinase C modulates in vitro phosphorylation of the smooth muscle heavy meromyosin by myosin light chain kinase, J. Biol. Chem., 259, 8808, 10.1016/S0021-9258(17)47225-5 · DOI
  94. Noris, 2013, Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study, Br. J. Haematol., 162, 112, 10.1111/bjh.12349 · DOI
  95. Noris, 2014, Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders, Blood, 124, e4, 10.1182/blood-2014-03-564328 · DOI
  96. Odronitz, 2007, Drawing the tree of eukaryotic life based on the analysis of 2,269 manually annotated myosins from 328 species, Genome Biol., 8, R196, 10.1186/gb-2007-8-9-r196 · DOI
  97. O'Seaghdha, 2011, The MYH9/APOL1 region and chronic kidney disease in European-Americans, Hum. Mol. Genet., 20, 2450, 10.1093/hmg/ddr118 · DOI
  98. Pecci, 2008, Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease, Hum. Mutat., 29, 409, 10.1002/humu.20661 · DOI
  99. Pecci, 2008, Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome), Nephrol. Dial. Transplant., 23, 2690, 10.1093/ndt/gfn277 · DOI
  100. Pecci, 2009, Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation, Thromb. Haemost., 102, 90, 10.1160/TH09-01-0068 · DOI
  101. Pecci, 2010, Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations, Blood, 116, 5832, 10.1182/blood-2010-08-304725 · DOI
  102. Pecci, 2011, Mutations responsible for MYH9-related thrombocytopenia impair SDF-1-driven migration of megakaryoblastic cells, Thromb. Haemost., 106, 693, 10.1160/TH11-02-0126 · DOI
  103. Pecci, 2012, Alteration of liver enzymes is a feature of the MYH9-related disease syndrome, PLoS One, 7, e35986, 10.1371/journal.pone.0035986 · DOI
  104. Pecci, 2012, Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation, Thromb. Haemost., 107, 1188, 10.1160/TH12-01-0005 · DOI
  105. Pecci, 2014, MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations, Hum. Mutat., 35, 236, 10.1002/humu.22476 · DOI
  106. Pecci, 2014, Cochlear implantation is safe and effective in patients with MYH9-related disease, Orphanet J. Rare Dis., 9, 100, 10.1186/1750-1172-9-100 · DOI
  107. Peterson, 1985, Fechtner syndrome—a variant of Alport's syndrome with leukocyte inclusions and macrothrombocytopenia, Blood, 65, 397, 10.1182/blood.V65.2.397.397 · DOI
  108. Raab, 2012, Crawling from soft to stiff matrix polarizes the cytoskeleton and phosphoregulates myosin-II heavy chain, J. Cell Biol., 199, 669, 10.1083/jcb.201205056 · DOI
  109. Rai, 2017, Myosin IIA heavy chain phosphorylation mediates adhesion maturation and protrusion in three dimensions, J. Biol. Chem., 292, 3099, 10.1074/jbc.M116.733402 · DOI
  110. Ramagopal, 2013, Structure of the S100A4/myosin-IIA complex, BMC Struct. Biol., 13, 31, 10.1186/1472-6807-13-31 · DOI
  111. Ravid, 2014, The tumor suppressor Lgl1 regulates front-rear polarity of migrating cells, Cell Adhes. Migr., 8, 378, 10.4161/cam.29387 · DOI
  112. Rocca, 1993, Fechtner syndrome: report of a third family and literature review, Br. J. Haematol., 85, 423, 10.1111/j.1365-2141.1993.tb03193.x · DOI
  113. Sandquist, 2008, The C-terminal tail region of nonmuscle myosin II directs isoform-specific distribution in migrating cells, Mol. Biol. Cell, 19, 5156, 10.1091/mbc.e08-05-0533 · DOI
  114. Saposnik, 2014, Mutation spectrum and genotype-phenotype correlations in a large French cohort of MYH9-related disorders, Mol. Genet. Genomic Med., 2, 297, 10.1002/mgg3.68 · DOI
  115. Savoia, 2010, Heavy chain myosin 9-related disease (MYH9 -RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder, Thromb. Haemost., 103, 826, 10.1160/TH09-08-0593 · DOI
  116. Schramek, 2014, Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas, Science, 343, 309, 10.1126/science.1248627 · DOI
  117. Sebé-Pedrós, 2014, Evolution and classification of myosins, a paneukaryotic whole-genome approach, Genome Biol. Evol., 6, 290, 10.1093/gbe/evu013 · DOI
  118. Sekine, 2010, Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease, Kidney Int., 78, 207, 10.1038/ki.2010.21 · DOI
  119. Seri, 2000, Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium, Nat. Genet., 26, 103, 10.1038/79063 · DOI
  120. Seri, 2003, MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness, Medicine (Baltimore), 82, 203, 10.1097/01.md.0000076006.64510.5c · DOI
  121. Shutova, 2014, Endogenous species of mammalian nonmuscle myosin IIA and IIB include activated monomers and heteropolymers, Curr. Biol., 24, 1958, 10.1016/j.cub.2014.07.070 · DOI
  122. Shutova, 2017, Self-sorting of nonmuscle myosins IIA and IIB polarizes the cytoskeleton and modulates cell motility, J. Cell Biol., 216, 2877, 10.1083/jcb.201705167 · DOI
  123. Sloan-Heggen, 2016, Comprehensive genetic testing in the clinical evaluation of 1119 patients with hearing loss, Hum. Genet., 135, 441, 10.1007/s00439-016-1648-8 · DOI
  124. Sellers, 2000, Myosins: a diverse superfamily, Biochim. Biophys. Acta, 2000, 3, 10.1016/S0167-4889(00)00005-7 · DOI
  125. Sellers, 1981, Reversible phosphorylation of smooth muscle myosin, heavy meromyosin, and platelet myosin, J. Biol. Chem., 256, 13137, 10.1016/S0021-9258(18)43018-9 · DOI
  126. Suzuki, 2013, Establishment of mouse model of MYH9 disorders: heterozygous R702C mutation provokes macrothrombocytopenia with leukocyte inclusion bodies, renal glomerulosclerosis and hearing disability, PLoS One, 8, 10.1371/journal.pone.0071187 · DOI
  127. Takeda, 2003, Ablation and mutation of nonmuscle myosin heavy chain II-B results in a defect in cardiac myocyte cytokinesis, Circ. Res., 93, 330, 10.1161/01.RES.0000089256.00309.CB · DOI
  128. Thon, 2012, Platelets: production, morphology and ultrastructure, Handb. Exp. Pharmacol., 210, 3, 10.1007/978-3-642-29423-5_1 · DOI
  129. Thon, 2012, Does size matter in platelet production?, Blood, 120, 1552, 10.1182/blood-2012-04-408724 · DOI
  130. Thon, 2012, Microtubule and cortical forces determine platelet size during vascular platelet production, Nat. Commun., 3, 852, 10.1038/ncomms1838 · DOI
  131. Totsukawa, 2000, Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts, J. Cell Biol., 150, 797, 10.1083/jcb.150.4.797 · DOI
  132. Tzur, 2010, Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene, Hum. Genet., 128, 345, 10.1007/s00439-010-0861-0 · DOI
  133. Verver, 2015, R705H mutation of MYH9 is associated with MYH9-related disease and not only with non-syndromic deafness DFNA17, Clin. Genet., 88, 85, 10.1111/cge.12438 · DOI
  134. Verver, 2016, Nonmuscle myosin heavy chain IIA mutation predicts severity and progression of sensorineural hearing loss in patients with MYH9-related disease, Ear Hear., 37, 112, 10.1097/AUD.0000000000000198 · DOI
  135. Vicente-Manzanares, 2009, Non-muscle myosin II takes centre stage in cell adhesion and migration, Nat. Rev. Mol. Cell Biol., 10, 778, 10.1038/nrm2786 · DOI
  136. Wang, 2010, Nonmuscle myosin II isoform and domain specificity during early mouse development, Proc. Natl. Acad. Sci. U. S. A., 107, 14645, 10.1073/pnas.1004023107 · DOI
  137. Wendt, 1999, Visualization of head-head interactions in the inhibited state of smooth muscle myosin, J. Cell Biol., 147, 1385, 10.1083/jcb.147.7.1385 · DOI
  138. Wu, 2013, Application of massively parallel sequencing to genetic diagnosis in multiplex families with idiopathic sensorineural hearing impairment, PLoS One, 8
  139. Yamanouchi, 2015, A novel MYH9 mutation in a patient with MYH9 disorders and platelet size-specific effect of romiplostim on macrothrombocytopenia, Ann. Hematol., 94, 1599, 10.1007/s00277-015-2416-x · DOI
  140. Ye, 2017, MicroRNA-647 targets SRF-MYH9 axis to suppress invasion and metastasis of gastric Cancer, Theranostics, 7, 3338, 10.7150/thno.20512 · DOI
  141. Zhang, 2012, Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A, Blood, 119, 238, 10.1182/blood-2011-06-358853 · DOI
  142. Zhu, 2017, MYBPH inhibits vascular smooth muscle cell migration and attenuates neointimal hyperplasia in a rat carotid balloon-injury model, Exp. Cell Res., 359, 154, 10.1016/j.yexcr.2017.07.036 · DOI

Cited by

See all 325

Metadata

Authors
Pecci, A., Ma, X., Savoia, A., & Adelstein, R. S.
ORCID
Pecci, Alessandro
Venue
Gene
Publisher
Elsevier BV
Published
2018-07
Volume
664
Pages
152-167
ISSN
0378-1119
DOI
10.1016/j.gene.2018.04.048
PMC
PMC5970098
Cited by
325
References
0
Language
en
Licence
Funders
  • Telethon Foundation (GGP17106)
  • Fondazione IRCCS Policlinico San Matteo
  • NHLBI
  • NIH
  • IRCCS Burlo Garofolo

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MYH9: Structure, functions and role of non-muscle myosin IIA in human disease. https://app.cochat.ai/papers/10.1016/j.gene.2018.04.048
The paper
Pecci, A., Ma, X., Savoia, A., & Adelstein, R. S. (2018). MYH9: Structure, functions and role of non-muscle myosin IIA in human disease. Gene. https://doi.org/10.1016/j.gene.2018.04.048